Leaflet PADVIRAM 600mg / 200mg / 245mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: efavirenz + emtricitabine + tenofovir disoproxil (non-nucleoside reverse transcriptase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitor + antiretroviral)
ATC: J05AR06 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
This medicine may affect the kidneys.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
The combination of Efavirenz + Emtricitabine + Tenofovir disoproxil is used for the treatment of HIV-1 infection in adults and adolescents. It combines a non-nucleoside reverse transcriptase inhibitor (efavirenz) with two nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil) to suppress viral replication.
The medication is taken orally, usually once daily, and is effective in reducing viral load and increasing CD4 cell counts. It is used as part of combination antiretroviral therapy.
Side effects may include nausea, dizziness, insomnia, rash, and, in rare cases, liver or kidney impairment. Regular monitoring of liver and kidney function is essential.
Consult your doctor to discuss the benefits and risks of treatment with this combination. Follow the prescribed dosage and adhere to all medical recommendations.
General data about PADVIRAM 600mg / 200mg / 245mg
- Substance: efavirenz + emtricitabine + tenofovir disoproxil
- Date of latest medicines list: 01-05-2018
- Product code: W64194002
- Concentration: 600mg / 200mg / 245mg
- Pharmaceutical form: film-coated tablets
- Quantity: 90
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.